Printer Friendly

NEUROMEDICA ALLOWED PATENT FOR TARDIVE DYSKINESIA THERAPEUTICS

 CAMBRIDGE, Mass., Aug. 26 /PRNewswire/ -- Neuromedica, Inc. today announced that it has received a notice of allowance from the US Patent and Trademark Office for a patent covering a class of pharmaceutical compounds for the treatment of tardive dyskinesia.
 Tardive dyskinesia is frequently a serious neurological condition characterized by uncontrolled movements of the lips, tongue, and jaw. According to the American Psychiatric Association, tardive dyskinesia occurs in more than 20 percent of patients receiving long term antipsychotic drug therapy. No effective and safe pharmaceutical products have been approved for the treatment of tardive dyskinesia, which can become a disabling condition requiring constant care and supervision.
 The claims allowed in the Neuromedica patent cover the treatment of tardive dyskinesia with dopamingergic agents linked to fatty acids that promote uptake into the brain. Neuromedica's first product under development is Doprexin(TM), synthesized by linking the neurotransmitter dopamine to the fatty acid DHA (docosahexaenoic acid). The neurotransmitter and the fatty acid are both natural brain components.
 Doprexin has been tested by Neuromedica and others in an animal model of tardive dyskinesia. Dr. Victor E. Shashoua, the company's chairman and chief scientist noted "The biological activity of Doprexin in animal studies suggests that the compound may be a promising treatment for tardive dyskinesia. We are currently expanding our pre- clinical testing program in preparation for filing an IND."
 The tardive dyskinesia patent is the third US patent awarded to Neuromedica. The previous patents have covered the use of certain fatty acids as brain access carriers and the application of Doprexin to appetite suppression. Neuromedica's president and CEO, Dr. Nigel Webb, commented, "We are encouraged by the allowance of this patent. Neuromedica is in discussion with a number of pharmaceutical companies regarding the clinical evaluation of Doprexin for the treatment of tardive dyskinesia."
 Neuromedica is a privately-held neuropharmaceutical company based in Cambridge, Mass. The company was founded in 1991 to develop therapeutic products using blood-brain carrier technology pioneered by Dr. Shashoua while at Harvard Medical School. Major areas of strategic focus for the company include: 1.) small molecule neuroactive pharmaceuticals for the treatment of tardive dyskinesia, obesity and other medical conditions; and 2.) neurotrophic (nerve cell growth) peptides for the treatment of neurological disorders such as Alzheimer's disease and stroke.
 -0- 8/26/93 R
 /Contact: Dr. Nigel Webb, president and CEO of Neuromedica, 617-492-9200/


CO: Nueromedica, Inc. ST: Massachusetts IN: MTC SU:

DD -- NE003 -- 6446 08/27/93 02:10 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Aug 27, 1993
Words:407
Previous Article:BRIO INDUSTRIES INC. MAKES ANNOUNCEMENT REGARDING 400,000 UNIT PRIVATE PLACEMENT
Next Article:TERADYNE FILES SUIT AGAINST INNOVATE LTD.
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters